Adenoid  ||| S:0 E:8 ||| JJ
hypetrophy ||| S:8 E:18 ||| NN
:  ||| S:18 E:20 ||| :
definition  ||| S:20 E:31 ||| NN
of  ||| S:31 E:34 ||| IN
some  ||| S:34 E:39 ||| DT
risk  ||| S:39 E:44 ||| NN
factors  ||| S:44 E:52 ||| NNS
Adenoids  ||| S:52 E:61 ||| RB
removed  ||| S:61 E:69 ||| VBN
for  ||| S:69 E:73 ||| IN
airway  ||| S:73 E:80 ||| JJ
obstruction  ||| S:80 E:92 ||| NN
and-or  ||| S:92 E:99 ||| JJ
recurrent  ||| S:99 E:109 ||| JJ
infections  ||| S:109 E:120 ||| NNS
have  ||| S:120 E:125 ||| VBP
been  ||| S:125 E:130 ||| VBN
studied  ||| S:130 E:138 ||| VBN
to  ||| S:138 E:141 ||| TO
identify  ||| S:141 E:150 ||| VB
a  ||| S:150 E:152 ||| DT
possible  ||| S:152 E:161 ||| JJ
mechanism  ||| S:161 E:171 ||| NN
to  ||| S:171 E:174 ||| TO
explain  ||| S:174 E:182 ||| VB
chronicity ||| S:182 E:192 ||| NNS
.  ||| S:192 E:194 ||| .
In  ||| S:194 E:197 ||| IN
this  ||| S:197 E:202 ||| DT
regard ||| S:202 E:208 ||| NN
,  ||| S:208 E:210 ||| ,
macrophages  ||| S:210 E:222 ||| NNS
may  ||| S:222 E:226 ||| MD
play  ||| S:226 E:231 ||| VB
a  ||| S:231 E:233 ||| DT
relevant  ||| S:233 E:242 ||| JJ
pathogenic  ||| S:242 E:253 ||| JJ
role  ||| S:253 E:258 ||| NN
as  ||| S:258 E:261 ||| IN
well  ||| S:261 E:266 ||| RB
as  ||| S:266 E:269 ||| IN
neutrophils  ||| S:269 E:281 ||| NN
during  ||| S:281 E:288 ||| IN
bacterial  ||| S:288 E:298 ||| JJ
infections  ||| S:298 E:309 ||| NNS
and  ||| S:309 E:313 ||| CC
eosinophils  ||| S:313 E:325 ||| NN
in  ||| S:325 E:328 ||| IN
allergic  ||| S:328 E:337 ||| JJ
inflammation ||| S:337 E:349 ||| NN
.  ||| S:349 E:351 ||| .
Therefore ||| S:351 E:360 ||| RB
,  ||| S:360 E:362 ||| ,
this  ||| S:362 E:367 ||| DT
study  ||| S:367 E:373 ||| NN
aimed  ||| S:373 E:379 ||| VBN
at  ||| S:379 E:382 ||| IN
investigating  ||| S:382 E:396 ||| VBG
some  ||| S:396 E:401 ||| DT
mediators  ||| S:401 E:411 ||| NN
as  ||| S:411 E:414 ||| IN
surrogate  ||| S:414 E:424 ||| JJ
markers  ||| S:424 E:432 ||| NN
of  ||| S:432 E:435 ||| IN
inflammation  ||| S:435 E:448 ||| NN
in  ||| S:448 E:451 ||| IN
children  ||| S:451 E:460 ||| NNS
who  ||| S:460 E:464 ||| WP
had  ||| S:464 E:468 ||| VBD
to  ||| S:468 E:471 ||| TO
undergo  ||| S:471 E:479 ||| VB
to  ||| S:479 E:482 ||| TO
adenoidectomy ||| S:482 E:495 ||| VB
.  ||| S:495 E:497 ||| .
Globally ||| S:497 E:505 ||| RB
,  ||| S:505 E:507 ||| ,
67  ||| S:507 E:510 ||| CD
children  ||| S:510 E:519 ||| NNS
( ||| S:519 E:520 ||| -LRB-
25  ||| S:520 E:523 ||| CD
females ||| S:523 E:530 ||| NNS
,  ||| S:530 E:532 ||| ,
42  ||| S:532 E:535 ||| CD
males ||| S:535 E:540 ||| NNS
,  ||| S:540 E:542 ||| ,
mean  ||| S:542 E:547 ||| JJ
age  ||| S:547 E:551 ||| NN
4.9  ||| S:551 E:555 ||| CD
years ||| S:555 E:560 ||| NNS
) ||| S:560 E:561 ||| -RRB-
,  ||| S:561 E:563 ||| ,
affected  ||| S:563 E:572 ||| VBN
by  ||| S:572 E:575 ||| IN
persistent  ||| S:575 E:586 ||| JJ
obstruction  ||| S:586 E:598 ||| NN
caused  ||| S:598 E:605 ||| VBN
by  ||| S:605 E:608 ||| IN
adenoid  ||| S:608 E:616 ||| JJ
hypertrophy  ||| S:616 E:628 ||| NN
were  ||| S:628 E:633 ||| VBD
consecutively  ||| S:633 E:647 ||| JJ
enrolled  ||| S:647 E:656 ||| NN
into  ||| S:656 E:661 ||| IN
the  ||| S:661 E:665 ||| DT
study ||| S:665 E:670 ||| NN
.  ||| S:670 E:672 ||| .
Blood  ||| S:672 E:678 ||| NN
samples  ||| S:678 E:686 ||| NNS
were  ||| S:686 E:691 ||| VBD
collected  ||| S:691 E:701 ||| VBN
from  ||| S:701 E:706 ||| IN
patients  ||| S:706 E:715 ||| NNS
and  ||| S:715 E:719 ||| CC
controls  ||| S:719 E:728 ||| NNS
to  ||| S:728 E:731 ||| TO
determine  ||| S:731 E:741 ||| VB
serum  ||| S:741 E:747 ||| JJ
CD163 ||| S:747 E:752 ||| NN
,  ||| S:752 E:754 ||| ,
Myeloperoxidase  ||| S:754 E:770 ||| NNP
( ||| S:770 E:771 ||| -LRB-
MPO ||| S:771 E:774 ||| NNP
)  ||| S:774 E:776 ||| -RRB-
and  ||| S:776 E:780 ||| CC
ECP ||| S:780 E:783 ||| NNP
.  ||| S:783 E:785 ||| .
There  ||| S:785 E:791 ||| EX
were  ||| S:791 E:796 ||| VBD
significant  ||| S:796 E:808 ||| JJ
differences  ||| S:808 E:820 ||| NNS
between  ||| S:820 E:828 ||| IN
patients  ||| S:828 E:837 ||| NNS
and  ||| S:837 E:841 ||| CC
controls  ||| S:841 E:850 ||| NNS
for  ||| S:850 E:854 ||| IN
serum  ||| S:854 E:860 ||| CD
CD163  ||| S:860 E:866 ||| CD
( ||| S:866 E:867 ||| -LRB-
p  ||| S:867 E:869 ||| RB
less  ||| S:869 E:874 ||| JJR
than  ||| S:874 E:879 ||| IN
0.0001 ||| S:879 E:885 ||| CD
) ||| S:885 E:886 ||| -RRB-
;  ||| S:886 E:888 ||| :
MPO  ||| S:888 E:892 ||| NNP
( ||| S:892 E:893 ||| -LRB-
p  ||| S:893 E:895 ||| RB
less  ||| S:895 E:900 ||| JJR
than  ||| S:900 E:905 ||| IN
0.0001 ||| S:905 E:911 ||| CD
) ||| S:911 E:912 ||| -RRB-
;  ||| S:912 E:914 ||| :
serum  ||| S:914 E:920 ||| JJ
ECP  ||| S:920 E:924 ||| NNP
( ||| S:924 E:925 ||| -LRB-
p  ||| S:925 E:927 ||| RB
less  ||| S:927 E:932 ||| JJR
than  ||| S:932 E:937 ||| IN
0.0001 ||| S:937 E:943 ||| CD
) ||| S:943 E:944 ||| -RRB-
.  ||| S:944 E:946 ||| .
This  ||| S:946 E:951 ||| DT
study  ||| S:951 E:957 ||| NN
demonstrated  ||| S:957 E:970 ||| VBD
some  ||| S:970 E:975 ||| DT
risk  ||| S:975 E:980 ||| NN
factors  ||| S:980 E:988 ||| NNS
for  ||| S:988 E:992 ||| IN
severe  ||| S:992 E:999 ||| JJ
AH ||| S:999 E:1001 ||| NNP
:  ||| S:1001 E:1003 ||| :
apnoea ||| S:1003 E:1009 ||| CD
,  ||| S:1009 E:1011 ||| ,
recurrent  ||| S:1011 E:1021 ||| JJ
respiratory  ||| S:1021 E:1033 ||| JJ
infections ||| S:1033 E:1043 ||| NNS
,  ||| S:1043 E:1045 ||| ,
and  ||| S:1045 E:1049 ||| CC
high  ||| S:1049 E:1054 ||| JJ
serum  ||| S:1054 E:1060 ||| NN
CD163  ||| S:1060 E:1066 ||| CD
levels ||| S:1066 E:1072 ||| NNS
.  ||| S:1072 E:1074 ||| .
